MA41547B1 - Formulation de poudre nasale pour le traitement de l'hypoglycémie - Google Patents

Formulation de poudre nasale pour le traitement de l'hypoglycémie

Info

Publication number
MA41547B1
MA41547B1 MA41547A MA41547A MA41547B1 MA 41547 B1 MA41547 B1 MA 41547B1 MA 41547 A MA41547 A MA 41547A MA 41547 A MA41547 A MA 41547A MA 41547 B1 MA41547 B1 MA 41547B1
Authority
MA
Morocco
Prior art keywords
powder formulation
treatment
hypoglycemia
nasal powder
relates
Prior art date
Application number
MA41547A
Other languages
English (en)
Inventor
Sankaram B Mantripragada
Claude A Piche
Betsbrugge Jo Jan Filip Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41547(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41547B1 publication Critical patent/MA41547B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une formulation de poudre contenant du glucagon ou un analogue de glucagon, à administrer par voie nasale, utile dans le traitement de l'hypoglycémie, et en particulier dans le traitement d'une hypoglycémie grave. La présente invention concerne également un procédé de fabrication de cette formulation de poudre, et des dispositifs et procédés d'utilisation de ladite formulation de poudre.
MA41547A 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie MA41547B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17
EP16710352.2A EP3258919B2 (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie
PCT/US2016/018003 WO2016133863A1 (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie

Publications (1)

Publication Number Publication Date
MA41547B1 true MA41547B1 (fr) 2020-04-30

Family

ID=55538593

Family Applications (3)

Application Number Title Priority Date Filing Date
MA41547A MA41547B1 (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA052252A MA52252A (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA052253A MA52253A (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA052252A MA52252A (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA052253A MA52253A (fr) 2015-02-17 2016-02-16 Formulation de poudre nasale pour le traitement de l'hypoglycémie

Country Status (41)

Country Link
US (3) US10213487B2 (fr)
EP (3) EP3258919B2 (fr)
JP (3) JP6522144B2 (fr)
KR (1) KR102121443B1 (fr)
CN (1) CN107278154B (fr)
AU (2) AU2016220235B2 (fr)
BR (1) BR112017014994B1 (fr)
CA (1) CA2975562C (fr)
CL (1) CL2017002031A1 (fr)
CO (1) CO2017008148A2 (fr)
CR (1) CR20170373A (fr)
CY (1) CY1122716T1 (fr)
DK (1) DK3258919T4 (fr)
DO (1) DOP2017000179A (fr)
EA (1) EA034820B1 (fr)
EC (1) ECSP17053843A (fr)
ES (1) ES2775498T5 (fr)
FI (1) FI3258919T4 (fr)
GT (1) GT201700179A (fr)
HR (1) HRP20200222T4 (fr)
HU (1) HUE049413T2 (fr)
IL (1) IL253273B (fr)
LT (1) LT3258919T (fr)
MA (3) MA41547B1 (fr)
MD (1) MD3258919T3 (fr)
MX (1) MX376200B (fr)
MY (1) MY175669A (fr)
NZ (1) NZ734035A (fr)
PE (1) PE20171334A1 (fr)
PH (1) PH12017501486A1 (fr)
PL (1) PL3258919T5 (fr)
PT (1) PT3258919T (fr)
RS (1) RS59918B2 (fr)
SA (1) SA517382068B1 (fr)
SG (1) SG11201705640PA (fr)
SI (1) SI3258919T2 (fr)
SV (1) SV2017005515A (fr)
TN (1) TN2017000349A1 (fr)
UA (1) UA121874C2 (fr)
WO (1) WO2016133863A1 (fr)
ZA (2) ZA201704944B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
CA3012679C (fr) 2016-01-29 2023-12-12 Mannkind Corporation Inhalateur a poudre seche
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
EP3668490A4 (fr) 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Compositions de poudre sèche pour administration intranasale
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
WO2019060761A1 (fr) * 2017-09-21 2019-03-28 The Scripps Research Institute Nouvelles thérapies destinées à traiter et prévenir une rhino-sinusite chronique
TWI771669B (zh) * 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US20210283053A1 (en) 2020-03-16 2021-09-16 Zealand Pharma A/S Liquid formulations of glucagon analogues
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
CN119454909B (zh) * 2025-01-13 2025-04-08 上海世领制药有限公司 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (fr) 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Composition pharmaceutique et son application
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1106888C (zh) 1998-03-10 2003-04-30 瓦卢瓦股份有限公司 容器、容器的灌注方法及容器中流体制品的分配装置
WO1999047160A1 (fr) 1998-03-13 1999-09-23 Novo Nordisk A/S Solutions peptidiques aqueuses stabilisees
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
US6522144B2 (en) 2000-12-22 2003-02-18 Ge Medical Systems Global Technology Company, Llc RF shielding method and apparatus for an open MRI system
WO2003066669A2 (fr) 2002-02-04 2003-08-14 Millipore Corporation Procede visant a extraire des agregats de proteines et des virus d'une solution proteinique
CN100515511C (zh) 2003-10-09 2009-07-22 株式会社;生命科学活效 鼻腔用粉状药剂施药装置
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
WO2007065156A2 (fr) 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Formulation pharmaceutique pour la permeabilite epitheliale accrue de peptide de regulation du glucose
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP2158214B1 (fr) 2007-06-15 2011-08-17 Zealand Pharma A/S Analogues du glucagon
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
EP2370462B1 (fr) 2008-12-15 2014-07-16 Zealand Pharma A/S Analogues du glucagon
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2011013003A2 (fr) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Granisétron pour administration intranasale et applicateur nasal
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
EP2552951A1 (fr) 2010-03-26 2013-02-06 Novo Nordisk A/S Nouveaux analogues du glucagon
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
MX355364B (es) 2011-05-27 2018-04-16 Collazo Handal Jose Schafik Bebida para la reposición rápida de iones calcio en el torrente sanguíneo.
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
IN2014CN04401A (fr) 2011-12-23 2015-09-04 Zealand Pharma As
EP3248642B1 (fr) 2012-06-28 2020-04-08 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Système de distribution de poudre sèche nasale pour vaccins et d'autres agents de traitement
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal

Also Published As

Publication number Publication date
AU2021203035B2 (en) 2023-07-13
ES2775498T3 (es) 2020-07-27
MD3258919T3 (ro) 2023-04-30
JP7362687B2 (ja) 2023-10-17
PT3258919T (pt) 2020-03-26
JP7094242B2 (ja) 2022-07-01
US10213487B2 (en) 2019-02-26
ES2775498T5 (es) 2023-01-31
AU2016220235B2 (en) 2021-04-29
TN2017000349A1 (en) 2019-01-16
MA52252A (fr) 2021-02-17
PL3258919T3 (pl) 2020-08-10
ECSP17053843A (es) 2017-11-30
SI3258919T2 (sl) 2023-01-31
EP3258919B1 (fr) 2020-01-15
SV2017005515A (es) 2018-08-27
CR20170373A (es) 2017-09-18
EP3258919A1 (fr) 2017-12-27
JP2021107418A (ja) 2021-07-29
PE20171334A1 (es) 2017-09-13
US12370241B2 (en) 2025-07-29
CN107278154B (zh) 2021-04-09
RS59918B2 (sr) 2023-01-31
JP2018507852A (ja) 2018-03-22
KR20170103934A (ko) 2017-09-13
UA121874C2 (uk) 2020-08-10
CA2975562C (fr) 2020-04-28
CL2017002031A1 (es) 2018-03-23
EP3258919B2 (fr) 2022-11-09
EP3673899B1 (fr) 2025-06-25
CN107278154A (zh) 2017-10-20
GT201700179A (es) 2018-11-23
EA201791560A1 (ru) 2018-02-28
ZA201704944B (en) 2021-05-26
FI3258919T4 (fi) 2023-02-09
DOP2017000179A (es) 2017-08-31
HUE049413T2 (hu) 2020-09-28
IL253273A0 (en) 2017-08-31
HRP20200222T4 (hr) 2022-12-23
DK3258919T3 (da) 2020-03-23
AU2021203035A1 (en) 2021-06-10
EP3673899C0 (fr) 2025-06-25
BR112017014994B1 (pt) 2023-12-19
RS59918B1 (sr) 2020-03-31
KR102121443B1 (ko) 2020-06-10
AU2016220235A1 (en) 2017-07-20
PL3258919T5 (pl) 2023-02-27
MD3258919T2 (ro) 2020-07-31
EP3673900B1 (fr) 2025-06-25
MX2017010572A (es) 2017-12-07
EP3673900A1 (fr) 2020-07-01
US20180000904A1 (en) 2018-01-04
US12226456B2 (en) 2025-02-18
JP6522144B2 (ja) 2019-05-29
BR112017014994A2 (pt) 2018-03-20
CY1122716T1 (el) 2021-03-12
SA517382068B1 (ar) 2020-10-26
LT3258919T (lt) 2020-02-25
EA034820B1 (ru) 2020-03-25
WO2016133863A1 (fr) 2016-08-25
JP2019147817A (ja) 2019-09-05
SI3258919T1 (sl) 2020-03-31
EP3673899A1 (fr) 2020-07-01
DK3258919T4 (da) 2022-11-21
MA52253A (fr) 2021-02-17
SG11201705640PA (en) 2017-08-30
HRP20200222T1 (hr) 2020-05-29
CO2017008148A2 (es) 2017-11-30
US20190282666A1 (en) 2019-09-19
MY175669A (en) 2020-07-03
PH12017501486A1 (en) 2018-01-15
ZA201901241B (en) 2020-10-28
MX376200B (es) 2025-03-07
IL253273B (en) 2019-08-29
EP3673900C0 (fr) 2025-06-25
CA2975562A1 (fr) 2016-08-25
US20230302093A1 (en) 2023-09-28
NZ734035A (en) 2019-06-28

Similar Documents

Publication Publication Date Title
MA41547B1 (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
FR25C1042I1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP3895717C0 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer colorectal, comprenant weissella cibaria wikim28 en tant que substance active
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
MA41051B1 (fr) Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
MA45675B1 (fr) Procédés et compositions pour le traitement du cancer
JOP20200004A1 (ar) تركيبات طويلة المفعول
EP3731846A4 (fr) Systèmes d'administration de médicament pour le traitement d'infections
MA46548A (fr) Fsh pour le traitement de l'infertilité
EP3324944A4 (fr) Systèmes d'administration de médicaments intravitréens pour le traitement d'états oculaires
MA41203B1 (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39496A (fr) Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x
EP3650029A4 (fr) Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine
MA39230A1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MX2017010630A (es) Derivado de imidazopirimidina e imidazotriazina, y composicion farmaceutica que lo comprende.
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
EP3406626A4 (fr) Peptide pour traitement du cancer, et composition pharmaceutique contenant celui-ci